
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. has raised its FY26 EPS estimate to $(4.17) from a previous $(8.63), indicating improved financial projections driven by a higher share count. The upcoming approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud software platform, is expected to significantly enhance the company’s market presence and revenue potential. Additionally, the anticipated FDA approval of its first diagnostic algorithm by the first half of 2026 further underscores the substantial growth opportunities that lie ahead for HeartSciences.
Bears say
HeartSciences Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily due to balance sheet and liquidity risks, as well as the potential failure of its product candidates to prove safety and efficacy during clinical trials. The company's fiscal year 2026 revenue estimates have drastically decreased from $1.2 million to $0.1 million, largely due to delays in obtaining regulatory approvals from the FDA. Additionally, the company's ability to commercialize its products and secure suitable reimbursement in a competitive healthcare landscape poses further risks, compounded by changing macroeconomic conditions and shifting investor sentiment towards healthcare stocks.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares